 Home > Active Ingredient News > Drugs Articles > Novartis acquires Gyroscope, an ophthalmic gene therapy company, for $1.5 billion

Novartis acquires Gyroscope, an ophthalmic gene therapy company, for $1.5 billion

 Last Update: 2022-01-10
 Source: Internet
 Author: User

Tags

dry oil paint

dry solutions

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On December 22, Novartis announced an agreement with Gyroscope Therapeutics, a British ophthalmic gene therapy company, to acquire the issued shares of the latter with a down payment of US$800 million, potential mileage of US$700 million, and a total transaction value of US$1.

The core product GT005 of Gyroscope Therapeutics is a one-time gene therapy based on AAV2 vector, which is intended to be developed to treat age-related macular degeneration (AMD) secondary geographic atrophy

GT005 can restore the balance of the over-activated complement system by promoting the secretion of complement factor I (CFI), relieve eye inflammation, and protect eyesight

Age-related macular degeneration (AMD) is an eye disease that affects people's daily activities that require clear central vision (such as reading).

Gyroscope Therapeutics is currently conducting a phase I/II and two phase II studies to evaluate the efficacy and safety of GT005 on AMD secondary geographic atrophy

Novartis continues to increase its deployment in ophthalmology and gene therapy

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Reta 5mg 10mg 15mg Vial Weight Loss Anti-diabetes Fat Loss

CAS No.: 2381089-83-2

Pharmacy Grade

$110-130/UNIT FOB

Best price Pure Tirzepatide powder 10mg vial Tirzepatide CAS 2023788-19-2 ouda

CAS No.: 2023788-19-2

Pharmacy Grade

$40.00/G FOB

Hot Sale 1-Adamantanamine Hydrochloride /1-Adamantanamine HCl CAS 665-66-7

CAS No.: 665-66-7

Pharmacy Grade

$20-25/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.